The Spectrum and Profile of COVID-19 Infection and Its Impact on Liver.
NCT04345640 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1000
Last updated 2020-09-03
Summary
To address the existing deficiencies in the knowledge regarding liver involvement and spectrum of clinical presentation and the impact of COVID-19 infection in patients of liver disease was planned. The present study will be a hospital based and the cases of confirmed COVID-19 infection will be evaluated in relation to liver involvement irrespective of pre-existing liver disease. The primary objective was to address the clinical presentation, biochemical alteration and outcomes of COVID-19 infection in subjects with chronic hepatitis, cirrhosis in comparison to those having infection in the absence of pre-existing liver disease
Conditions
- Liver Cirrhoses
Interventions
- OTHER
-
no intervention
no intervention
Sponsors & Collaborators
-
Institute of Liver and Biliary Sciences, India
lead OTHER
Eligibility
- Min Age
- 18 Years
- Max Age
- 70 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-04-10
- Primary Completion
- 2020-12-31
- Completion
- 2020-12-31
Countries
- India
Study Locations
More Related Trials
-
An Online Survey to Understand Feelings Related to COVID-19 Among ILBS Patients With Liver Disease
NCT04352491 ·Status: COMPLETED
-
To Assess the Efficacy of High-Volume Plasma Exchange and GCSF Versus GCSF Alone in Patients of Acute on Chronic Liver Failure (ACLF).
NCT03162419 ·Status: WITHDRAWN ·Phase: NA
-
Safety and Efficacy of a Non-replicating ChAdOx1 Vector Vaccine AZD1222 (COVISHIELD), for Prevention of COVID-19 in Patients With Liver Cirrhosis
NCT04794946 ·Status: UNKNOWN ·Phase: NA
-
Metabolic Cofactor Supplementation in Obese Patients With Non-Alcoholic Fatty Liver Disease
NCT04330326 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD
NCT07194863 ·Status: NOT_YET_RECRUITING
-
Probiotics in NASH Patients - PROBILIVER TRIAL
NCT03467282 ·Status: UNKNOWN ·Phase: NA
-
Chinese CLIF-C Acute-on-Chronic Liver Disease and Liver Failure Study
NCT02457637 ·Status: COMPLETED
-
Regression of Liver Fibrosis After Daclatasvir and Asunaprevir Treatment
NCT02865369 ·Status: UNKNOWN
-
Ursodeoxycholic Acid in Patients With NAFLD - Clinical Observation
NCT05256979 ·Status: ACTIVE_NOT_RECRUITING
-
Evaluation of the Effectiveness of the Use of a Carnitine-Orotate Complex and Biphenyl Dimethyl Dicarboxylate in the Pathogenetic Therapy of Metabolic-associated Fatty Liver Disease: a Prospective Cohort Study
NCT06078722 ·Status: UNKNOWN
-
Fecal Microbiota Therapy Versus Standard Therapy in NASH Related Cirrhosis.
NCT02721264 ·Status: UNKNOWN ·Phase: NA
-
Effects of Fecal Microbiota Transplantation on Weight in Obese Patients With Non-alcoholic Fatty Liver Disease
NCT04594954 ·Status: UNKNOWN ·Phase: NA
-
Fecal Microbiota Therapy Versus Standard Therapy in Decompensated NASH Related Cirrhosis: A Randomized Controlled Trial.
NCT02868164 ·Status: WITHDRAWN ·Phase: NA
-
Transplantation for EASL-CLIF and APASL ACLF Patients: a Retrospective Cohort Study
NCT05036031 ·Status: UNKNOWN
-
Treatment of Nonalcoholic Fatty Liver Disease With Probiotics and Prebiotics
NCT00870012 ·Status: COMPLETED ·Phase: NA
-
Effect of Plasmapheresis on Clinical Improvement and Biological Parameters of Patients With Long-haul COVID
NCT05543590 ·Status: WITHDRAWN ·Phase: NA
-
Early Versus Routine Drain Removal After Live Liver Donor Hepatectomy
NCT04504487 ·Status: COMPLETED ·Phase: NA
-
Efficacy of a Natural Components Mixture in the Treatment of Non Alcoholic Fatty Liver Disease (NAFLD)
NCT02369536 ·Status: COMPLETED ·Phase: NA
-
Efficacy of Plasmapheresis in Patients of Drug-Induced Liver Injury (DILI) With Underlying Chronic Liver Disease
NCT06797011 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2/PHASE3
-
Study in Patients With Decompensated Liver Cirrhosis
NCT06380335 ·Status: ACTIVE_NOT_RECRUITING
-
Probiotics in the Treatment of NAFLD
NCT02764047 ·Status: UNKNOWN ·Phase: NA
-
Investigational Treatments for COVID-19 in Tertiary Care Hospital of Pakistan
NCT04492501 ·Status: COMPLETED ·Phase: NA
-
Development of Microbial Therapeutics for Metabolic-associated Fatty Liver Disease: From Mechanistic Investigations to Clinical Trials
NCT06873165 ·Status: RECRUITING ·Phase: NA
-
Intravenous NAC Use in ACLF Patients
NCT05089981 ·Status: UNKNOWN ·Phase: NA
-
Combination of Autologous MSC and HSC Infusion in Patients With Decompensated Cirrhosis
NCT04243681 ·Status: COMPLETED ·Phase: PHASE4